E
Euthalia Roussou
Researcher at Barking, Havering and Redbridge University Hospitals NHS Trust
Publications - 28
Citations - 5248
Euthalia Roussou is an academic researcher from Barking, Havering and Redbridge University Hospitals NHS Trust. The author has contributed to research in topics: Psoriatic arthritis & Rheumatoid arthritis. The author has an hindex of 15, co-authored 27 publications receiving 4330 citations. Previous affiliations of Euthalia Roussou include St George's Hospital.
Papers
More filters
Journal ArticleDOI
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Joachim Listing,Nurullah Akkoc,J Brandt,Jürgen Braun,C.T. Chou,Eduardo Collantes-Estevez,Maxime Dougados,Feng Huang,Jieruo Gu,Muhammad Asim Khan,Yesim Kirazli,Walter P. Maksymowych,Herman Mielants,Inge Juul Sørensen,Salih Ozgocmen,Euthalia Roussou,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,Joachim Sieper +22 more
TL;DR: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial spondyloarthritis in those with chronic back pain.
Journal ArticleDOI
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Nurullah Akkoc,J Brandt,C.T. Chou,Maxime Dougados,Feng Huang,Jieruo Gu,Yesim Kirazli,F. Van den Bosch,Ivana Olivieri,Euthalia Roussou,Salvatore Scarpato,Inge Juul Sørensen,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,J. Sieper +18 more
TL;DR: The new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis, particularly regarding sensitivity.
Journal ArticleDOI
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash,Bruce Kirkham,Masato Okada,Proton Rahman,B. Combe,Gerd Burmester,David H. Adams,Lisa Kerr,Chin Lee,Catherine L Shuler,Mark C. Genovese,Khalid Ahmed,Jeffrey Alper,Nichol Barkham,Ralph E. Bennett,Francisco Javier Blanco Garcia,Ricardo Blanco Alonso,Howard B. Blumstein,Michael S. Brooks,Gerd R Burmester,Patricia Cagnoli,Paul H. Caldron,Alain Cantagrel,Der Yuan Chen,Melvin Churchill,Christine E Codding,Peter M.G. Deane,Jose Del Giudice,Atul Deodhar,Rajat K. Dhar,Eva Dokoupilova,Rita M. Egan,Andrea Everding,Eva Galíndez,David H. Goddard,Alice B. Gottlieb,Philippe Goupille,Robert M. Griffin,Ramesh C. Gupta,Stephen B. Hall,Kalpita Hatti,Mary P. Howell,Yu-Huei Huang,Ramina Jajoo,Namieta M. Janssen,Uta Kiltz,Alan Kivitz,Steven J. Klein,Mariusz P. Korkosz,Roshan Kotha,Joel M. Kremer,Cummins Lue,José Luis Marenco de la Fuente,Helena Marzo-Ortega,Jordi Gratacós Masmitjà,Philip J. Mease,Pier Luigi Meroni,Eric C. Mueller,Anupama C. Nandagudi,Antonio Fernández-Nebro,Clark M. Neuwelt,Ana Maria Orbai,Meera R. Oza,Deborah L. Parks,Debendra Pattanaik,Maria Rell-Bakalarska,David H. Rosmarin,Euthalia Roussou,Anna I. Rychlewska-Hanczewksa,David H. Sikes,Michael T. Stack,Prashanth Sunkureddi,Hasan Tahir,Diamant Thaçi,Tsen-Fang Tsai,Anthony M. Turkiewicz,Leonore Unger,Raúl Veiga Cabello,Ulf Wagner,Cheng Chung Wei,Alvin F. Wells,Peter Youssef,Agnieszka Zielinska +82 more
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.
Journal ArticleDOI
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell,Philip S. Helliwell,Oliver FitzGerald,Jaap Fransen,Dafna D. Gladman,Gerald G Kreuger,Kristina Callis-Duffin,Neil McHugh,Philip J. Mease,Vibeke Strand,Robin Waxman,Valderílio Feijó Azevedo,Adriana Beltran Ostos,Sueli Carneiro,Alberto Cauli,Luis R Espinoza,John A. Flynn,Nada Hassan,Paul J. Healy,Eduardo Kerzberg,Yun Jong Lee,Ennio Lubrano,Antonio Marchesoni,Helena Marzo-Ortega,Giovanni Porru,Elvia G. Moreta,Peter Nash,Helena Raffayova,Roberto Ranza,Siba P. Raychaudhuri,Euthalia Roussou,Raphael Scarpa,Yeong Wook Song,Enrique R. Soriano,Paul P. Tak,Ilona Ujfalussy,Kurt de Vlam,Jessica A. Walsh +37 more
TL;DR: Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.
Journal ArticleDOI
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Simon J. Bowman,Colin C Everett,John O’Dwyer,Paul Emery,Costantino Pitzalis,Wan-Fai Ng,Colin T. Pease,Elizabeth Price,Nurhan Sutcliffe,Nagui Gendi,Frances Hall,Sharon Ruddock,Catherine Fernandez,Catherine Reynolds,Claire Hulme,Kevin A. Davies,Christopher J Edwards,Peter Lanyon,Robert J. Moots,Euthalia Roussou,Ian Giles,Linda D. Sharples,Michele Bombardieri +22 more
TL;DR: In this paper, the authors investigated whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjogren's syndrome (SS).